We found that the letter detection rate increased with the onset time (F = 2.88, p = 0.009), except for the last onset time (765 810 ms), which was associated with a decreased letter detection rate.
This treatment improved PD patients deficits such as reduction in speed during the writing task and decrease in letter size (micrographia).
Visual acuity has been shown to decrease as letters are moved further from the centre of fixation, resulting in the loss of visual information.
We assumed that, each year, a patient's visual acuity would either increase by 15 letters, remain the same, decrease by 15 letters, or decrease by 30 letters.
We assumed that, each year, a patient's visual acuity would increase by 15 letters, remain the same, decrease by 15 letters, or decrease by 30 letters.
Over the 12-month study period, ranibizumab-treated patients had a mean average gain in BCVA of 7.8 letters compared with baseline, whereas sham patients had a mean average decrease of 0.1 letter.
There was a mean increase of 6.5 and 7.2 letters in 0.3 mg and 0.5 mg groups, respectively, versus a mean decrease of 10.2 letters in the sham group.
Mean increases in VA from baseline were 6.5 letters for the ranibizumab 0.3 mg group and 7.2 letters for the ranibizumab 0.5 mg group, whereas sham-injected patients had a mean decrease of 10.4 letters.
Similarly, deletions and contractions are considered to be reducing operations, decreasing by one letter the length of the string.
Given that the probability of encountering a particular letter decreases with increasing distance this is likely to produce a length effect.
